These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 27139984)

  • 1. Evolution of frameworks for expediting access to new drugs in Japan.
    Fujiwara Y
    Nat Rev Drug Discov; 2016 May; 15(5):293-4. PubMed ID: 27139984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Japanese universal health care faces a crisis in cancer treatment.
    Fujiwara Y; Yonemori K; Shibata T; Okita N; Ushirozawa N
    Lancet Oncol; 2015 Mar; 16(3):251-2. PubMed ID: 25752548
    [No Abstract]   [Full Text] [Related]  

  • 3. Children's clinical cancer trials: what needs to change to allow children access to new cancer drugs?
    Moreno L; Pearson AD
    Expert Rev Clin Pharmacol; 2015; 8(6):665-7. PubMed ID: 26307367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of the US Accelerated Approval for New Anticancer Drugs on Time to Verification of Benefit and Regulatory Approval in the EU and Japan.
    Ito A; Narukawa M
    Ther Innov Regul Sci; 2024 Jan; 58(1):136-142. PubMed ID: 37787890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer Care Ontario's New Drug Funding Program: controlled introduction of expensive anticancer drugs.
    Evans WK; Nefsky M; Pater J; Browman G; Cowan DH
    Chronic Dis Can; 2002; 23(4):152-6. PubMed ID: 12517323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early market access of cancer drugs in the EU.
    Martinalbo J; Bowen D; Camarero J; Chapelin M; Démolis P; Foggi P; Jonsson B; Llinares J; Moreau A; O'Connor D; Oliveira J; Vamvakas S; Pignatti F
    Ann Oncol; 2016 Jan; 27(1):96-105. PubMed ID: 26487583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer care prioritised: Georgia expands access to cancer medicines.
    Khizanishvili G; Henshall S; Gabunia T
    Lancet Oncol; 2021 Jan; 22(1):15-17. PubMed ID: 33387493
    [No Abstract]   [Full Text] [Related]  

  • 8. Time to access to novel anticancer drugs and the correlation with ESMO-Magnitude of Clinical Benefit Scale in Slovenia.
    Janzic U; Knez L; Janzic A; Cufer T
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):717-723. PubMed ID: 31826655
    [No Abstract]   [Full Text] [Related]  

  • 9. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC; He L; He G; He Y
    J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Not available, cope with it: an unacceptable scandal].
    Aapro M; Dietrich PY; Leyvraz S
    Rev Med Suisse; 2012 May; 8(342):1083-4. PubMed ID: 22734175
    [No Abstract]   [Full Text] [Related]  

  • 11. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Strategy Group workshop. Improvements in patient access to new anti-cancer medicines.
    Br J Cancer; 1999 Jan; 79(1):2-3. PubMed ID: 10408683
    [No Abstract]   [Full Text] [Related]  

  • 12. The generic drug market in Japan: will it finally take off?
    Iizuka T; Kubo K
    Health Econ Policy Law; 2011 Jul; 6(3):369-89. PubMed ID: 21205400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ensuring Access to Injectable Generic Drugs - The Case of Intravesical BCG for Bladder Cancer.
    Davies BJ; Hwang TJ; Kesselheim AS
    N Engl J Med; 2017 Apr; 376(15):1401-1403. PubMed ID: 28402764
    [No Abstract]   [Full Text] [Related]  

  • 14. Health secretary demands patients have equal access to cancer drugs.
    Dyer O
    BMJ; 2003 Nov; 327(7422):1007. PubMed ID: 14593014
    [No Abstract]   [Full Text] [Related]  

  • 15. Balancing access and evaluation in the approval of new cancer drugs.
    Miller FG; Joffe S
    JAMA; 2011 Jun; 305(22):2345-6. PubMed ID: 21642688
    [No Abstract]   [Full Text] [Related]  

  • 16. Government's fund is improving access to drugs for patients with cancer.
    Kmietowicz Z
    BMJ; 2011 Dec; 343():d7918. PubMed ID: 22144413
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
    Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
    J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Report highlights European inequalities in access to cancer drugs.
    Eur J Cancer; 2005 Dec; 41(18):2779. PubMed ID: 16408332
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional Disparity in First-in-Class Anticancer Drug Development in the US, EU, and Japan.
    Hino Y; Okada M; Hallgreen CE; De Bruin ML; Doty RE; Matsumaru N; Tsukamoto K
    Biol Pharm Bull; 2023 May; 46(5):700-706. PubMed ID: 36878610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.